• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 13, 2014

View Archived Issues

Epirus touts biosimilar Remicade progress, boosting Zalicus shares

Shares of Zalicus Inc., the company that will soon give Epirus Pharmaceuticals Inc. entrée to the public market through a reverse merger, shot up 39.8 percent Thursday as Epirus promoted trial results showing that BOW015, its biosimilar to the anti-tumor necrosis factor therapy Remicade (infliximab, Johnson & Johnson) compared favorably to the branded drug in a phase III equivalence trial. Read More

Adcom splits on endorsing CVOTs for PAMORA class in OIC

Drug developers and analysts seeking to handicap the outcome of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (adcom) meeting might have left scratching their heads after a day and a half of sponsor and agency presentations. Read More

China gets billion-dollar boost toward national level consolidation

SHANGHAI – China's distribution sector took a big step toward consolidation with the announcement that Sinopharm Group Co. Ltd and Shanghai Fosun Group Co. Ltd. would form a joint venture (JV) to create what promises to be the first nationwide drug and medical device network. Read More

Mexican standoff in Europe over authorized off-label Avastin use

The decision by the European Federation of Pharmaceutical Industries Association (EFPIA) to go public this week on Italy's and France's embrace of off-label use of medicines represents a further escalation of an issue it has previously campaigned on behind closed doors. Read More

Solid tumors may also respond to kinase inhibitor drugs

LONDON – A strategy of boosting the immune response against cancer, using a drug which has already delivered highly encouraging results for patients with leukemias and other hematological malignancies, may be equally successful when applied to solid tumors such as those of the breast and lung, new animal studies suggest. Read More

CFDA goes mobile, releases two apps to boost accessibility

HONG KONG – Looking to reach out to more users and drug companies and riding the wave of growth of online information and platforms to facilitate the sharing of information between governments and users, China's drug regulator is now using mobile technology as part of its communications strategy. Read More

Financings

Novavax Inc., of Gaithersburg, Md., said it closed its public offering, issuing about 28.8 million shares of common stock, including 3.8 million shares covering overallotments, at $4 apiece. Read More

Other news to note

Morphosys AG, of Martinsried, Germany, and Merck & Co. Inc., of Whitehouse Station, N.J., said they signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. Read More

Stock movers

Read More

In the clinic

Amgen Inc., of Thousand Oaks, Calif., and Astrazeneca plc, of London, reported phase II results in The New England Journal of Medicine, with data from the 168-patient study showing that brodalumab, a drug that targets the interleukin-17 receptor, significantly improved signs and clinical symptoms associated with psoriatic arthritis, including tender and swollen joints, at 12 weeks, as measured by a 20 percent improvement in the American College of Rheumatology (ACR20) response criteria. Read More

Pharma: Other news to note

Parion Sciences Inc., of Durham, N.C., and Osaka, Japan-based Santen Pharmaceutical Co. Ltd. agreed to jointly develop and commercialize Parion's experimental treatment for dry eye disease, P-321, in parts of Asia. Under the deal's terms, Santen will make an undisclosed option payment to secure certain rights to P-321 and to support the upcoming combination phase I/IIa trial of the drug. Read More

Pharma: In the clinic

Pfizer Inc., of New York, presented two abstracts on phase I studies evaluating the bioequivalence of its potential biosimilars to rituximab and infliximab at the European League Against Rheumatism congress in Paris. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Kymera’s phase I data lead big week for STAT6 space

    BioWorld
    It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe